Lead Product(s) : Enitociclib,Prednisone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vincerx Pharma Announces Clinical Efficacy Of Enitociclib in Lymphoma Treatment
Details : VIP152 (enitociclib) is a selective CDK9 inhibitor in Phase 1/2 trials with venetoclax and prednisone for lymphoma, reducing oncogenes MYC and MCL1.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2024
Lead Product(s) : Enitociclib,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Findings demonstrate that VIP152 monotherapy inhibits tumor growth in an ovarian cancer xenograft model in mice. VIP152, the PTEFb/CDK9 inhibitor, used for treatment in gynecologic cancer cell lines and in patients with gynecologic malignancies.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Enitociclib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VIP152, a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 inhibitor demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor effic...
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vincerx Pharma Provides Key Strategic Update
Details : VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Deerfield Management
Deal Size : $50.0 million
Deal Type : Private Placement
Vincerx Pharma Announces $50 Million Private Placement
Details : The proceeds from the financing will support the clinical evaluation of VIP152, the Company’s potent and selective inhibitor of CDK9, in additional indications and combination regimens, as well as to advance its bioconjugation platform.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Deerfield Management
Deal Size : $50.0 million
Deal Type : Private Placement
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orphan Drug Designation is based on ongoing Phase 1b expansion of VIP152, PTEFb/CDK9 inhibitor in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors.
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vincera Pharma Announces Exclusive License Agreement with Bayer for Oncology Portfolio
Details : Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer...
Product Name : VIP152
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 10, 2020
Lead Product(s) : Enitociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement